Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovis ABFRA:5GV 92 EV-to-EBITDA is 34.79 as of Aug. 17, 2026, which is 36% below its 10-year median of 54.61. GuruFocus rates FRA:5GV with a GF Score™ of 92/100 and a GF Value™ of €2.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 401 Biotechnology companies, Genovis AB ranks worse than 76.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genovis AB's enterprise value is €111.71 Mil.
Genovis AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €3.21 Mil. Therefore, Genovis AB's EV-to-EBITDA for today is 34.79.
The historical rank and industry rank for Genovis AB's EV-to-EBITDA or its related term are showing as below:
FRA:5GV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -169.78 Med: 54.61 Max: 779.11
Current: 35.23
During the past 13 years, the highest EV-to-EBITDA of Genovis AB was 779.11. The lowest was -169.78. And the median was 54.61.
FRA:5GV's EV-to-EBITDA is ranked worse than 76.56% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs FRA:5GV: 35.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genovis AB's share price for today is €1.754.
Genovis AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Genovis AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5GV vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Genovis AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genovis AB's EV-to-EBITDA falls into.
Genovis AB's current Enterprise Value is €111.71 Mil.
Genovis AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (FRA:5GV) has a EV-to-EBITDA of 34.79 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genovis AB. This is 36% below median its historical median of 54.61. According to the industry distribution chart, Genovis AB ranks #307 out of 401 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Genovis AB's EV-to-EBITDA too high?
Genovis AB's current EV-to-EBITDA of 34.79 is 36% below median its 10-year median of 54.61. The Biotechnology industry median EV-to-EBITDA is 13.80. Genovis AB's value of 34.79 is 152.1% above this industry median. Based on the distribution chart, Genovis AB ranks #307 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genovis AB has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #307 out of 401 companies for EV-to-EBITDA. This places Genovis AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. Genovis AB's value of 34.79 is 152.1% above this benchmark. While the company's 10-year median is 54.61 vs. the industry median of 13.80, Genovis AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovis AB's current EV-to-EBITDA of 34.79 is 152.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genovis AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovis AB's current EV-to-EBITDA is 34.79, which is 36% below median its own 10-year median of 54.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (FRA:5GV) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.27, compared to a current price of €1.75 — trading 22.7% below its estimated fair value. The current EV-to-EBITDA is 34.79, which is 36% below median its 10-year median of 54.61 and 152.1% above the Biotechnology industry median of 13.80. Genovis AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current EV-to-EBITDA is 34.79 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (FRA:5GV) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of €1.75 is trading 22.7% below its estimated GF Value™ of €2.27.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for FRA:5GV:
EV-to-EBITDA: 34.79 (36% below median its 10-year median of 54.61)
GF Value™: €2.27 vs. price of €1.75 (22.7% below fair value)
Industry Position: 152.1% above the Biotechnology median (#307 of 401)
No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
92GF Score
Get the complete analysis for FRA:5GV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5GV has been successfully added to your 
